Ensysce Biosciences, Inc. (ENSC)
| Market Cap | 6.54M-82.7% |
| Revenue (ttm) | n/a |
| Net Income | n/a-91.8% |
| EPS | n/a+38.2% |
| Shares Out | 15.37M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 90,262.032 |
| Open | 0.44 |
| Previous Close | 0.43 |
| Day's Range | 0.41 - 0.44 |
| 52-Week Range | 0.23 - 2.75 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | n/a |
Ensysce Biosciences, Inc. has a live Insider Score.
Scored on 1 qualifying trade from 1 insider in the last 90 days.
About ENSC
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection. It is also developing PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for attention deficit hyperactivity disorder; and PF9001 to treat opioid use disorder. Further, It develops neuroplastogenic therapies and psychedelic-derived molecules for severe chronic pain, particularly complex regional pain syndrome (CRPS). Ensysce Biosciences, Inc. was founded in 2003 and is based in La Jolla, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$ENSC stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in ENSC holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ENSC's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ENSC Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ENSC patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ENSC from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ENSC
| ETF | Est. Holding Size |
|---|---|
| VXFVanguard Extended Market ETF | $5.05K |
Estimated from each fund’s disclosed top holdings × AUM
ENSC Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ENSC’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score